Literature DB >> 3998996

Strategies in the design of solution-stable, water-soluble prodrugs I: a physical-organic approach to pro-moiety selection for 21-esters of corticosteroids.

B D Anderson, R A Conradi, K E Knuth.   

Abstract

The ideal water-soluble prodrug should exhibit sufficient aqueous solution stability to allow long-term storage of its solutions (i.e., 2 years at room temperature) and yet should be converted rapidly in vivo to the active parent drug--two severe and seemingly conflicting demands which limit the utility of many common solubilizing pro-moieties. For example, succinate esters, which are commonly utilized as water-soluble prodrugs, are unstable in solution and may undergo slow and incomplete bioconversion in vivo. In this study, the solution stability problems associated with 21-esters of corticosteroids are reviewed. It is concluded that the most important reaction limiting shelf life is ester hydrolysis. From a consideration of the influence of molecular structure on ester reactivity, a strategy for the design of solution-stable, water-soluble prodrugs of corticosteroids has been developed. Two key requirements for dilute solution stability are high solubility at the pH of optimum stability and appropriate design of the pH-rate profile. Several 21-esters of methylprednisolone have been synthesized, and the rates of their aqueous solution hydrolysis have been determined to test the strategy. Compounds exhibiting estimated shelf lives in dilute solution of greater than 2 years at 25 degrees C have been identified.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3998996     DOI: 10.1002/jps.2600740402

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Effect of ionic strength on solution stability of PNU-67590A, a micellar prodrug of methylprednisolone.

Authors:  H Okamoto; K Mori; K Ohtsuka; H Ohuchi; H Ishii
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

2.  Preparation and characterization of inclusion complexes of a hemisuccinate ester prodrug of delta9-tetrahydrocannabinol with modified beta-cyclodextrins.

Authors:  Sampada B Upadhye; Swapnil J Kulkarni; Soumyajit Majumdar; Mitchell A Avery; Waseem Gul; Mahmoud A ElSohly; Michael A Repka
Journal:  AAPS PharmSciTech       Date:  2010-03-24       Impact factor: 3.246

3.  Microbial transformations and bioconversions. Patents and literature.

Authors:  R J Linhardt
Journal:  Appl Biochem Biotechnol       Date:  1986-12       Impact factor: 2.926

4.  Kinetics and mechanisms of activation of alpha-amino acid ester prodrugs of camptothecins.

Authors:  Lin Song; Robert Bevins; Bradley D Anderson
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

5.  Immediate inhibitory effect of methylprednisolone suleptanate (U-67590A) on antigen-induced cutaneous and airway anaphylactic responses in guinea-pigs.

Authors:  M Hashimoto; Y Shinozaki; M Katori
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

6.  The role of protein and lipid domains in the uptake of solutes by human stratum corneum.

Authors:  P V Raykar; M C Fung; B D Anderson
Journal:  Pharm Res       Date:  1988-03       Impact factor: 4.200

7.  Chemical and enzymatic degradation of ganciclovir prodrugs: enhanced stability of the diadamantoate prodrug under acid conditions.

Authors:  M F Powell; A Magill; N Chu; K Hama; C I Mau; L Foster; R Bergstrom
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

8.  Methylprednisolone pharmacokinetics after intravenous and oral administration.

Authors:  S M Al-Habet; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

9.  Stabilization of resveratrol in blood circulation by conjugation to mPEG and mPEG-PLA polymers: investigation of conjugate linker and polymer composition on stability, metabolism, antioxidant activity and pharmacokinetic profile.

Authors:  Basavaraj Siddalingappa; Heather A E Benson; David H Brown; Kevin T Batty; Yan Chen
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.